A Study to Evaluate the Efficacy of Venetoclax Monotherapy in Relapsed/Refractory Participants With Chronic Lymphocytic Leukemia (CLL)

Exclusion Criteria

• •Participant has developed Richter's transformation or Prolymphocytic leukemia
• •Participant has previously received venetoclax
• •History of active malignancies other than CLL within the past 2 years prior to first dose of venetoclax, with the exception of:
• •* adequately treated in situ carcinoma of the cervix uteri
• •* adequately treated basal cell carcinoma or localized squamous cell carcinoma of the skin
• •* previous malignancy confined and surgically resected (or treated with other modalities) with curative intent
• •Participant has active and uncontrolled autoimmune cytopenias (for 2 weeks prior to Screening), including autoimmune hemolytic anemia and idiopathic thrombocytopenic purpura despite low dose corticosteroids
• •Participant has undergone an allogeneic stem cell transplant
• •Treatment with any of the following within five half-lives or 14 days (if half-life unknown) as applicable prior to the first dose of venetoclax, or clinically significant adverse effect(s)/toxicity(s) of the previous therapy have not resolved to \< National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.03 Grade 2:
• •* Any anti-cancer therapy including chemotherapy, or radiotherapy;
• •* Investigational therapy, including targeted small molecule agents
• •Participant is human immunodeficiency virus (HIV) positive
• •Participant has known allergy to both xanthine oxidase inhibitors and rasburicase